NOS1AP gene polymorphism and body fat component in patients with schizophrenia: a search for associations

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

Long-term pharmacotherapy in patients with schizophrenia can provoke antipsychotic-induced obesity. This side effect does not always meet the criteria for metabolic syndrome (MS), primarily central obesity. However, this significantly reduces the quality of life of patients and is a risk factor for the development of many diseases. In humans, the NOS1AP gene product is involved in adipogenesis, dendrite maturation, mnemonic processes, and impulse transmission via NMDA receptors. We hypothesized that NOS1AP gene polymorphisms are associated with metabolic parameters in patients with schizophrenia. We examined 491 patients of Slavic nationalities with an established diagnosis of schizophrenia. All participants underwent anthropometric examination to determine waist circumference and total and visceral fat content using bioimpedance analysis and caliperometry. Biochemical parameters of blood serum were evaluated by standard methods. MS components were determined according to the International Diabetes Federation criteria. DNA was isolated from peripheral blood leukocytes by standard phenol-chloroform method. Three SNPs in the NOS1AP gene were selected for genotyping. The alleles of the studied polymorphisms were determined by real-time PCR. As a result, statistically significant differences in the groups of patients with different levels of visceral fat in the distribution of allele frequency of the s12143842 NOS1AP polymorphism, as well as differences in the levels of visceral fat depending on the rs10494366 NOS1AP genotype were revealed. For the first time, an association of NOS1AP gene polymorphisms with the formation of visceral fat levels in patients with schizophrenia was established. Results obtained can be further used to design genetic panels to predict the development of adverse metabolic effects during antipsychotic therapy for schizophrenia.

全文:

受限制的访问

作者简介

V. Tiguntsev

Mental Health Research of the Tomsk National Research Medical Center

编辑信件的主要联系方式.
Email: cristall2009@live.ru
俄罗斯联邦, Tomsk

I. Mednova

Mental Health Research of the Tomsk National Research Medical Center

Email: cristall2009@live.ru
俄罗斯联邦, Tomsk

D. Petkun

Mental Health Research of the Tomsk National Research Medical Center

Email: cristall2009@live.ru
俄罗斯联邦, Tomsk

A. Agarkov

Mental Health Research of the Tomsk National Research Medical Center

Email: cristall2009@live.ru
俄罗斯联邦, Tomsk

A. Kornetov

Siberian State Medical University

Email: cristall2009@live.ru
俄罗斯联邦, Tomsk

I. Pozhidaev

Mental Health Research of the Tomsk National Research Medical Center

Email: cristall2009@live.ru
俄罗斯联邦, Tomsk

D. Paderina

Mental Health Research of the Tomsk National Research Medical Center

Email: cristall2009@live.ru
俄罗斯联邦, Tomsk

E. Kornetova

Mental Health Research of the Tomsk National Research Medical Center

Email: cristall2009@live.ru
俄罗斯联邦, Tomsk

S. Ivanova

Mental Health Research of the Tomsk National Research Medical Center

Email: cristall2009@live.ru
俄罗斯联邦, Tomsk

参考

  1. Fedorenko O.Yu., Loonen A.J., Lang F., Toshchakova V.A., Boyarko E.G., Semke A.V., Bokhan N.A., Govorin N.V., Aftanas L.I., Ivanova S.A. (2015) Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. Int. J. Neuropsychopharmacol. 18(6), pyu098. https://doi.org/10.1093/ijnp/pyu098
  2. Ivanova S.A., Filipenko M.L., Vyalova N.M., Voronina E.N., Pozhidaev I.V., Osmanova D.Z., Ivanov M.V., Fedorenko O.Yu., Semke A.V., Bokhan N.A. (2016) CYP1A2 and CYP2D6 gene polymorphisms in schizophrenic patients with neuroleptic drug-induced side effects. Bull. Exp. Biol. Med. 160, 687‒690. doi: 10.1007/s10517-016-3250-4
  3. Lasić D., Bevanda M., Bošnjak N., Uglešić B., Glavina T., Franić T. (2014) Metabolic syndrome and inflammation markers in patients with schizophrenia and recurrent depressive disorder. Psychiatr. Danub. 26(3), 214–219.
  4. Смулевич А.Б., Сыркин А.Л., Дробижев М.Ю., Новикова Н.А., Гиляров М.Ю., Шорников С.Б., Бочарова М.В. (2007) Клинические особенности течения ишемической болезни сердца у больных шизофренией. Клиническая медицина. 85(4), 33–37.
  5. Suvisaari J., Keinanen J., Eskelinen S., Mantere O. (2016) Diabetes and schizophrenia. Curr. Diab. Rep. 16(2), 16. https://doi.org/10.1007/s11892-015-0704-4
  6. Bora E., Akdede B.B., Alptekin K. (2017) The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol. Med. 47(6), 1030–1040. https://doi.org/10.1017/ S0033291716003366
  7. Grover S., Sahoo S., Gopal S., Nehra R., Ganesh A., Raghavan V., Sankaranarayan A. (2019) Relationship of metabolic syndrome and neurocognitive deficits in patients with schizophrenia. Psychiatry Res. 278, 56–64. https://doi.org/10.1016/j.psychres.2019.05.023
  8. Smith E., Singh R., Lee J., Colucci L., Graff-Guerrero A., Remington G., Hahn M., Agarwal S.M. (2021) Adiposity in schizophrenia: a systematic review and meta-analysis. Acta Psychiatr. Scand. 144(6), 524536. https://doi.org/10.1111/acps.13365
  9. Корнетова Е.Г., Гончарова А.А., Меднова И.А., Корнетов А.Н., Саприна Т.В., Перчаткина О.Э., Семке А.В. (2023) Конституционально-морфологические основы метаболического синдрома у пациентов с шизофренией и лиц без психических расстройств. Бюллетень сибирской медицины. 22(1), 57–64. https://doi.org/10.20538/1682-0363-2023-1-57-64
  10. Алфимов П.В., Рывкин П.В., Ладыженский М.Я., Мосолов С.Н. (2014) Метаболический синдром у больных шизофренией (обзор литературы). Современная терапия психических расстройств. 3, 8–14.
  11. Morell R., Curtis J., Watkins A. (2019) Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication. Psychiatry Res. 281, 112606. https://doi.org/10.1016/j.psychres.2019.112606
  12. Postolache T.T., Del Bosque-Plata L., Jabbour S., Vergare M., Wu R., Gragnoli C. (2019) Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet. 180(3), 186–203. https://doi.org/10.1002/ajmg.b.32712
  13. Nasyrova R.F., Moskaleva P.V., Vaiman E.E., Shnayder N.A., Blatt N.L., Rizvanov A.A. (2020) Genetic factors of nitric oxide’s system in psychoneurologic disorders. Int. J. Mol. Sci. 21(5), 11–34. https://doi.org/10.3390/ijms21051604
  14. Matiiv A.B., Moskalenko S.E., Sergeeva O.S., Zhouravleva G.A., Bondarev S.A. (2022) NOS1AP interacts with α-synuclein and aggregates in yeast and mammalian cells. Int. J. Mol. Sci. 23(16), 9102. https://doi.org/10.3390/ijms23169102
  15. Hadzimichalis N.M., Previtera M.L., Moreau M.P., Li B., Lee G.H., Dulencin A.M., Matteson P.G., Buyske S., Millonig J.H., Brzustowicz L.M., Firestein B.L. (2010) NOS1AP protein levels are altered in BA46 and cerebellum of patients with schizophrenia. Schizophr. Res. 124, 248–250. https://doi.org/10.1016/j.schres.2010.05.009
  16. Zheng Y., Li H., Qin W., Chen W., Duan Y., Xiao Y., Li C., Zhang J., Li X., Feng G., He L. (2005) Association of the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. Biochem. Biophys. Res. Commun. 328, 809–815. https://doi.org/10.1016/j.bbrc.2005.01.037
  17. Miranda A., García J., López C., Gordon D., Palacio C., Restrepo G., Ortiz J., Montoya G., Cardeño C., Calle J., López M., Campo O., Bedoya G., Ruiz-Linares A., Ospina-Duque J. (2006) Putative association of the carboxy-terminal PDZ ligand of neuronal nitric oxide synthase gene (CAPON) with schizophrenia in a Colombian population. Schizophr. Res. 82, 283–285. https://doi.org/10.1016/j.schres.2005.10.018
  18. Zhang R., Chen F., Yu H., Gao L., Yin X., Dong Y., Yang Y., Xia Y. (2017) The genetic variation rs12143842 in NOS1AP increases idiopathic ventricular tachycardia risk in Chinese Han populations. Sci. Rep. 7(1), 8356. https://doi.org/10.1038/s41598-017-08548-z
  19. Shah S.A., Herrington D.M., Howard T.D., Divers J., Arnett D.K., Burke G.L., Hong Kao W., Guo X., Siscovick D.S., Chakravarti A., Lima J.A., Psaty B.M., Tomaselli G.F., Rich S.S., Bowden D.W., Post W. (2013) Associations between NOS1AP single nucleotide polymorphisms (SNPs) and QT interval duration in four racial/ethnic groups in the multi-ethnic study of atherosclerosis (MESA). Ann. Noninvasive Electrocardiol. 18, 29–40. https://doi.org/10.1111/anec.12028
  20. Pfeufer A., Sanna S., Arking D.E., Müller M., Gateva V., Fuchsberger C., Ehret G.B., Orrú M., Pattaro C., Köttgen A., Perz S., Usala G., Barbalic M., Li M., Pütz B., Scuteri A., Prineas R.J., Sinner M.F., Gieger C., Najjar S.S., Kao W.H., Mühleisen T.W., Dei M., Happle C., Möhlenkamp S., Crisponi L., Erbel R., Jöckel K.H., Naitza S., Steinbeck G., Marroni F., Hicks A.A., Lakatta E., Müller-Myhsok B., Pramstaller P.P., Wichmann H.E., Schlessinger D., Boerwinkle E., Meitinger T., Uda M., Coresh J, Kääb S., Abecasis G.R., Chakravarti A. (2009) Common variants at ten loci modulate the QT interval duration in the QTSCD study. Nat. Genet. 41(4), 407–414. https://doi.org/10.1038/ng.362
  21. Chu A.Y., Coresh J., Arking D.E., Pankow J.S., Tomaselli G.F., Chakravarti A., Post W.S., Spooner P.H., Boerwinkle E., Kao W.H.L. (2010) NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the atherosclerosis risk in communities (ARIC) study. Diabetologia. 53, 510–516.
  22. Boiko A.S., Pozhidaev I.V., Paderina D.Z., Bocharova A.V., Mednova I.A., Fedorenko O.Y., Kornetova E.G., Loonen A.J.M., Semke A.V., Bokhan N.A., Ivanova S.A. (2021) Search for possible associations of FTO gene polymorphic variants with metabolic syndrome, obesity and body mass index in schizophrenia patients. Pharmgenomics Pers. Med. 14, 1123–1131. https://doi.org/10.2147/PGPM.S327353
  23. Paderina D.Z., Boiko A.S., Pozhidaev I.V., Bocharova A.V., Mednova I.A., Fedorenko O.Y., Kornetova E.G., Loonen A.J.M., Semke A.V., Bokhan N.A., Ivanova S.A. (2021) Genetic polymorphisms of 5-HT receptors and antipsychotic-induced metabolic dysfunction in patients with schizophrenia. J. Pers. Med. 11(3), 181. https://doi.org/10.3390/jpm11030181
  24. Mednova I.A., Pozhidaev I.V., Tiguntsev V.V., Bocharova A.V., Paderina D.Z., Boiko A.S., Fedorenko O.Y., Kornetova E.G., Bokhan N.A., Stepanov V.A., Ivanova S.A. (2024) NOS1AP gene variants and their role in metabolic syndrome: a study of patients with schizophrenia. Biomedicines. 12(3), 627. https://doi.org/10.3390/biomedicines12030627
  25. Корнетова Е.Г., Гончарова А.А., Корнетов А.Н., Давыдов А.А., Дубровская В.В., Семке А.В., Бохан Н.А. (2018) Связь суицидального поведения и безнадежности с акатизией у больных шизофренией. Суицидология. 3(32), 63–70. https://doi.org/10.32878/suiciderus.18-09-03(32)-63-70
  26. Kay S.R., Fiszbein A., Opler L.A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2), 261–276.
  27. Мосолов С.Н. (2001) Шкалы психометрической оценки симптоматики шизофрении и концепция позитивных и негативных расстройств. Москва: Новый цвет, 238 с.
  28. Friedewald W.T., Levy R.I., Fredrickson D.S. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18(6), 499–502.
  29. Климов А.Н. (1977) Превентивная кардиология. Под ред. Косицкого Г.И. Москва: Медицина.
  30. Schwartz P.J., Crotti L., George A.L. Jr. (2018) Modifier genes for sudden cardiac death. Eur. Heart J. 39(44), 3925–3931. https://doi.org/10.1093/eurheartj/ehy502
  31. Kolder I.C.R.M., Tanck M.W.T., Postema P.G., Barc J., Sinner M.F., Zumhagen S., Husemann A., Stallmeyer B., Koopmann T.T., Hofman N., Pfeufer A., Lichtner P., Meitinger T., Beckmann B.M., Myerburg R.J., Bishopric N.H., Roden D.M., Kääb S., Wilde A.A.M., Schott J.J., Schulze-Bahr E., Bezzina C.R. (2015) Analysis for genetic modifiers of disease severity in patients with long-QT syndrome type 2. Circ. Cardiovasc. Genet. 8, 447–456. https://doi.org/10.1161/circgenetics.114.000785
  32. Lahrouchi N., Tadros R., Crotti L., Mizusawa Y., Postema P.G., Beekman L., Walsh R., Hasegawa K., Barc J., Ernsting M., Turkowski K.L., Mazzanti A., Beckmann B.M., Shimamoto K., Diamant U.B., Wijeyeratne Y.D., Kucho Y., Robyns T., Ishikawa T., Arbelo E., Christiansen M., Winbo A., Jabbari R., Lubitz S.A., Steinfurt J., Rudic B., Loeys B., Shoemaker M.B., Weeke P.E., Pfeiffer R., Davies B., Andorin A., Hofman N., Dagradi F., Pedrazzini M., Tester D.J., Bos J.M., Sarquella-Brugada G., Campuzano Ó., Platonov P.G., Stallmeyer B., Zumhagen S., Nannenberg E.A., Veldink J.H., van den Berg L.H., Al-Chalabi A., Shaw C.E., Shaw P.J., Morrison K.E., Andersen P.M., Müller-Nurasyid M., Cusi D., Barlassina C., Galan P., Lathrop M., Munter M., Werge T., Ribasés M., Aung T., Khor C.C., Ozaki M., Lichtner P., Meitinger T., van Tintelen J.P., Hoedemaekers Y., Denjoy I., Leenhardt A., Napolitano C., Shimizu W., Schott J.J., Gourraud J.B., Makiyama T., Ohno S., Itoh H., Krahn A.D., Antzelevitch C., Roden D.M., Saenen J., Borggrefe M., Odening K.E., Ellinor P.T., Tfelt-Hansen J., Skinner J.R., van den Berg M.P., Olesen M.S., Brugada J., Brugada R., Makita N., Breckpot J., Yoshinaga M., Behr E.R., Rydberg A., Aiba T., Kääb S., Priori S.G., Guicheney P., Tan H.L., Newton-Cheh C., Ackerman M.J., Schwartz P.J., Schulze-Bahr E., Probst V., Horie M., Wilde A.A., Tanck M.W.T., Bezzina C.R. (2020) Transethnic genome-wide association study provides insights in the genetic architecture and heritability of long QT syndrome. Circulation. 142(4), 324‒338. https://doi.org/10.1161CIRCULATIONAHA.120. 045956
  33. Bovolini A., Garcia J., Andrade M.A., Duarte J.A. (2021) Metabolic syndrome pathophysiology and predisposing factors. Int. J. Sports Med. 42(3), 199–214. https://doi.org/10.1055/a-12630898
  34. Ruiz-Castell M., Samouda H., Bocquet V., Fagherazzi G., Stranges S., Huiart L. (2021) Estimated visceral adiposity is associated with risk of cardiometabolic conditions in a population based study. Sci. Rep. 11(1), 9121. https://doi.org/10.1038/ s41598-021-88587-9
  35. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., Lieberman J.A. (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80(1), 19‒32. https://doi.org/10.1016/j.schres.2005.07.014

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russian Academy of Sciences, 2025